W21
Clean MeatCellular AgricultureMachine Learning
Active

Orbillion Bio

Premium cultivated meat at low cost

Intro to Orbillion Bio: https://youtu.be/Rql0eteqQ-o Orbillion Bio will be the first company to bring premium lab grown meat to the market. We will replace prime beef and wagyu with an ethical alternative that tastes amazing. The founders Patricia Bubner, PhD, Samet Yildirim, MSc, MBS and Gabriel Levesque-Tremblay, PhD have over 30 years of combined experience in business and product development, bioprocessing and biopharma. After only 4 months of development time, Orbillion has four different flavorful meats growing in the lab: wagyu beef, elk, sheep and American bison. Using their proprietary platform technology, Orbillion is rapidly decreasing the cost of cultivated meat. Major investors in our pre seed round were Y Combinator, New Protein Fund, Joyance Partners and Venture Souq. https://www.orbillion.com/

Patricia Bubner

Patricia is a scientist and engineer with a background in high-throughput screening, automation, process analytics and development. She has a broad industry experience in biopharma and clean energy (Boehringer Ingelheim, Sila Nanotechnologies). She has an MSc and PhD in chemistry and biotechnology. During her postdoc at UC Berkeley, she co-founded themilletproject.org, that aimed at diversifying agriculture and our diet through cultivation and consumption of lesser-known grains such as millets.

Patricia Bubner
Orbillion Bio

Gabriel Levesque-Tremblay

Gabriel Levesque Tremblay, PhD has 10+ years of experience in business development, synthetic biology and grant management. Prior to co-founding Orbillion, Gabriel was the Director of the Technical Business at AIChE where he grew 8M$ of sustainable revenues including the Food Innovation and Engineering (FOODIE) and the Emerging Meat Alternatives conference (EMAC). Gabriel also lead the strategic management of large grant initiatives from various grant agencies including DOD, DOE, NSF and NIH.

Gabriel Levesque-Tremblay
Orbillion Bio

Samet Yildirim

Samet has 10+ years of experience in commercializing biotechnologies. Samet was the Global Head of Innovation in the Boehringer Ingelheim's Biopharma Business Unit where he led the development and commercialization of biomanufacturing technologies. Prior to that, Samet held various positions within responsibilities for product innovation and business development in life science companies. He received a BSc in Biology and an MSc in Biophysics and business masters (MBS) in bioprocessing.

Samet Yildirim
Orbillion Bio